Anthera Pharmaceuticals Stock Current Valuation
Valuation analysis of Anthera Pharmaceuticals helps investors to measure Anthera Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Anthera Pharmaceuticals Company Current Valuation Analysis
Anthera Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Anthera Pharmaceuticals Current Valuation | (7.47 M) |
Most of Anthera Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anthera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Anthera Pharmaceuticals has a Current Valuation of (7.47 Million). This is 100.05% lower than that of the Biotechnology sector and 100.16% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.04% higher than that of the company.
Anthera Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anthera Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Anthera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anthera Pharmaceuticals by comparing valuation metrics of similar companies.Anthera Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Anthera Fundamentals
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | (7.47 M) | ||||
| Shares Outstanding | 26.18 M | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (0.20) X | ||||
| Price To Book | 0.11 X | ||||
| Gross Profit | (28.49 M) | ||||
| EBITDA | (26.59 M) | ||||
| Net Income | (26.87 M) | ||||
| Cash And Equivalents | 8.09 M | ||||
| Cash Per Share | 0.31 X | ||||
| Debt To Equity | 1.61 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (36.9 M) | ||||
| Short Ratio | 2.09 X | ||||
| Earnings Per Share | (1.76) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | -108.04 | ||||
| Market Capitalization | 617.83 K | ||||
| Total Asset | 3.67 M | ||||
| Retained Earnings | (436.8 M) | ||||
| Working Capital | 39.39 M | ||||
| Current Asset | 47.86 M | ||||
| Current Liabilities | 8.47 M | ||||
| Net Asset | 3.67 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |